Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (201-210 of 426) with videos related to

Pageof 43
Sort By:
Biorxiv : the Preprint Server for Biology|November 28, 2023
Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancerKaitriana E Colling, Emily L Symons, Lorenzo Buroni, et al.
Oncotarget|December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapyRaquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2019
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics servicesCathryn A Moss, Elena Cojocaru, Janet Hanwell, et al.
Investigational New Drugs|April 29, 2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyYohann Loriot, Karim Fizazi, Robert J Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityJ S de Bono, S Y Rha, J Stephenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2015
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsK Fizazi, T W Flaig, M Stöckle, et al.
Journal of Visualized Experiments : Jove|January 22, 2024
Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of CancerKaitriana E Colling, Emily L Symons, Lorenzo Buroni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyDenis C Talbot, Malcolm Ranson, Joanna Davies, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2013
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumorsShahneen K Sandhu, Kyri Papadopoulos, Peter C Fong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsTimothy A Yap, Laura Vidal, Jan Adam, et al.
Pageof 43

Showing results (201-210 of 426) with videos related to

Sort By:
Pageof 43
Biorxiv : the Preprint Server for Biology|November 28, 2023
Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancerKaitriana E Colling, Emily L Symons, Lorenzo Buroni, et al.
Oncotarget|December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapyRaquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2019
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics servicesCathryn A Moss, Elena Cojocaru, Janet Hanwell, et al.
Investigational New Drugs|April 29, 2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyYohann Loriot, Karim Fizazi, Robert J Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityJ S de Bono, S Y Rha, J Stephenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2015
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsK Fizazi, T W Flaig, M Stöckle, et al.
Journal of Visualized Experiments : Jove|January 22, 2024
Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of CancerKaitriana E Colling, Emily L Symons, Lorenzo Buroni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyDenis C Talbot, Malcolm Ranson, Joanna Davies, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2013
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumorsShahneen K Sandhu, Kyri Papadopoulos, Peter C Fong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsTimothy A Yap, Laura Vidal, Jan Adam, et al.
Pageof 43